to the regulator, dated Oct. 29, said that lack of demand in the trading bloc did not justify submitting further required data on its manufacturing plan.
"At this point Lilly is not in a position to generate the additional data required by the CHMP to progress to a formal marketing authorization application," the company said. The news comes on the day that the U.S. government agreed to buy 614,000 additional doses of Lilly's antibody combo for $1.29 billion, which follows the purchase of 388,000 doses of etesevimab in September to supplement stocks of bamlanivimab it had previously bought.The United States had already given emergency approval for the drug cocktail for patients at an early stage of the disease to prevent deterioration and for some people who have been exposed to the virus.
Even though the EU in September procured 220,000 courses of bamlanivimab and etesevimab, contingent on approval, the EU Commission in mid-October omitted the combination from aThe EU in March signed a deal with Roche for an antibody cocktail developed with Regeneron, and in July struck another deal for GlaxoSmithKline